ASH Highlights
- Continuing Education
Deliver timely, disease-specific updates from the ASH Annual Meeting to equip hematologists, oncologists, and other clinicians with the knowledge to identify, understand, and apply emerging therapies in the treatment of blood cancers.
On This Page
Overview
This activity is designed to educate hematologists, oncologists and other clinicians on new developments in the diagnosis and treatment of all blood cancers. Through disease specific lectures, highlighting the most clinically relevant data presented at the ASH Annual Meeting, attendees will be able to identify and describe the emerging treatments available and to utilize these treatments available in their professional practice.
The American Society of Hematology’s annual meeting in December is the venue at which cutting edge therapeutic advances are presented publicly for the first time. Unfortunately, only a small fraction of practitioners can attend this meeting. It is therefore of vital importance for practitioners and, in turn, their patients to have access to emerging data in a timely fashion. At this one-day activity, attendees will receive relevant updates on advances in acute leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, Waldenstrom’s macroglobulinemia, coagulation disorders, hematopoietic stem cell transplantation and CAR-T therapies.
Learning Objectives
- Describe an overview and highlight the recent medical advances present at the Annual Meeting of the American Society of Hematologists (ASH) which will help physicians achieve better patient outcomes.
- Recognize appropriate management and treatment options for hematologic malignancies.
- Utilize these approaches in routine clinical practice.
- Review new therapies and approaches in non-malignant hematology.
Developed and Offered By:
Continuing Education courses are developed by faculty from Harvard Medical School's teaching hospitals and accredited by Harvard Medical School. This course is offered by Dana Farber Cancer Insititue.
Schedule
All agenda sessions are in Eastern Time.
Saturday, January 24, 2026
Welcome and Introduction
9:00-9:10 am
Transplant Highlights
9:10-9:50 am
Leukemia Highlights
9:50-10:30 am
Hematology Highlights
10:30-11:10 am
Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
11:10-11:50 am
Break
11:50 am-12:05 pm
CLL Highlights
12:05-12:45 pm
Multiple Myeloma Highlights
12:45-1:25 pm
Lymphoma Highlights
1:25-2:05 pm
CAR-T Highlights
2:05-2:45 pm
Closing Remarks
2:45-2:55 pm
Faculty
Harvard Medical School Continuing Education attracts the best and brightest faculty from all around the world. As a student in this course, you’ll have access to outstanding course directors and faculty.
Ann S. LaCasce
MD | Course Director
Inhye Ahn, MD
Nathan T. Connell, MD, MPH
Jean Connors, MD
Jennifer Crombie, MD
Corey Cutler, MD
Daniel DeAngelo, MD, PhD
Tera Feldman, MA, PA-C
Mahasweta Gooptu, MBBS, MD
Caron Jacobson, MD
Shonali Midha, MD
Caitlin Murphy, APRN, DNP, FNP
Richard Stone, MD
Kaitlin Stratton
Request Information
Interested in learning more about this program? Sign up for details.
Course Fees
Fee Disclaimer
You may register through our secure online environment and will receive an email confirmation upon receipt of your payment. Virtual tuition includes electronic syllabus and access to recordings for 60 days after the course.
At the end of the registration process, a $10 non-refundable processing fee will be added to your registration.
| Role | Course Fee |
|---|---|
| Physician (MD/DO) | $75.00 |
| Nurse (RN/APRN) | $75.00 |
| PA | $75.00 |
| Psychologist | $75.00 |
| Resident/Fellow | $75.00 |
| Social Worker | $75.00 |
| Allied Health Professional / Other | $75.00 |